"In the first quarter of 2017 we will know the safety, magnitude of drug effect, significance of the response, time to onset, and repeatability across two, well controlled studies," said Stasko.
Pharmaceutical stocks have been held in check this year, partly due to worries about pricing scrutiny from a Hillary Clinton administration. Stasko believes the enhanced price scrutiny is warranted, but the isolated attacks on individual manufacturers or branded products that aren't being actively promoted is unjustified.
"No one is talking about the price increases of generics which are prescribed 10 times, 100 times, or 1000 times more frequently in some cases compared to branded alternatives," said Stasko. "We should really be assessing the total impact on the system and resolving those challenges."